| Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis M Paez-Ribes, E Allen, J Hudock, T Takeda, H Okuyama, F Viñals, ... Cancer cell 15 (3), 220-231, 2009 | 2785 | 2009 |
| Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation E Allen, A Jabouille, LB Rivera, I Lodewijckx, R Missiaen, V Steri, K Feyen, ... Science translational medicine 9 (385), eaak9679, 2017 | 629 | 2017 |
| Consensus guidelines for the use and interpretation of angiogenesis assays P Nowak-Sliwinska, K Alitalo, E Allen, A Anisimov, AC Aplin, R Auerbach, ... Angiogenesis 21, 425-532, 2018 | 553 | 2018 |
| Metabolic symbiosis enables adaptive resistance to anti-angiogenic therapy that is dependent on mTOR signaling E Allen, P Miéville, CM Warren, S Saghafinia, L Li, MW Peng, D Hanahan Cell Reports 15 (6), 1144-1160, 2016 | 205 | 2016 |
| Mice expressing a mutant desmosomal cadherin exhibit abnormalities in desmosomes, proliferation, and epidermal differentiation. E Allen, QC Yu, E Fuchs The Journal of cell biology 133 (6), 1367-1382, 1996 | 181 | 1996 |
| Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition E Allen, IB Walters, D Hanahan Clinical Cancer Research 17 (16), 5299-5310, 2011 | 157 | 2011 |
| Gigaxonin-controlled degradation of MAP1B light chain is critical to neuronal survival E Allen, J Ding, W Wang, S Pramanik, J Chou, V Yau, Y Yang Nature 438 (7065), 224-228, 2005 | 152 | 2005 |
| Gigaxonin interacts with tubulin folding cofactor B and controls its degradation through the ubiquitin-proteasome pathway W Wang, J Ding, E Allen, P Zhu, L Zhang, H Vogel, Y Yang Current Biology 15 (22), 2050-2055, 2005 | 105 | 2005 |
| Gene targeting of GAN in mouse causes a toxic accumulation of microtubule-associated protein 8 and impaired retrograde axonal transport J Ding, E Allen, W Wang, A Valle, C Wu, T Nardine, B Cui, J Yi, A Taylor, ... Human molecular genetics 15 (9), 1451-1463, 2006 | 90 | 2006 |
| BPAG1n4 is essential for retrograde axonal transport in sensory neurons JJ Liu, J Ding, AS Kowal, T Nardine, E Allen, JD Delcroix, C Wu, ... The Journal of cell biology 163 (2), 223-229, 2003 | 84 | 2003 |
| Giant axonal neuropathy Y Yang, E Allen, J Ding, W Wang Cellular and molecular life sciences 64, 601-609, 2007 | 63 | 2007 |
| Development of a bioluminescent nitroreductase probe for preclinical imaging AG Vorobyeva, M Stanton, A Godinat, KB Lund, GG Karateev, KP Francis, ... PLoS One 10 (6), e0131037, 2015 | 49 | 2015 |
| Randomized controlled trial and economic evaluation of nurse-led group support for young mothers during pregnancy and the first year postpartum versus usual care J Barnes, J Stuart, E Allen, S Petrou, J Sturgess, J Barlow, G Macdonald, ... Trials 18, 1-15, 2017 | 41 | 2017 |
| Nemitin, a novel Map8/Map1s interacting protein with Wd40 repeats W Wang, VF Lundin, I Millan, A Zeng, X Chen, J Yang, E Allen, N Chen, ... PloS one 7 (4), e33094, 2012 | 19 | 2012 |
| Microtubule-associated protein 8 contains two microtubule binding sites J Ding, A Valle, E Allen, W Wang, T Nardine, Y Zhang, L Peng, Y Yang Biochemical and biophysical research communications 339 (1), 172-179, 2006 | 15 | 2006 |
| Therapeutic induction of high endothelial venules (HEVs) to enhance T-cell infiltration in tumors E Allen, R Missiaen, G Bergers Oncotarget 8 (59), 99207, 2017 | 9 | 2017 |
| Abstract B16: Anti‐angiogenic therapy using brivanib, a combined VEGF and FGF pathway inhibitor, in a mouse model of pancreatic neuroendocrine cancer (PNET), results in … E Allen, IB Walters, IC Rivera, D Hanahan Molecular Cancer Therapeutics 8 (12_Supplement), B16-B16, 2009 | 6 | 2009 |
| Trimming the vascular tree in tumors: metabolic and immune adaptations E Allen, R Missiaen, G Bergers Cold Spring Harbor symposia on quantitative biology 81, 21-29, 2016 | 5 | 2016 |
| an FGF/VEGF inhibitor, is differentially active 1st vs. 2nd line against mouse PNET tumors developing evasive/adaptive resistance to VEGF inhibition E Allen, I Walters, DB Hanahan Clin. Cancer Res 17, 5299-5310, 2011 | 4 | 2011 |
| Bacteriophage-based nanoprobe targeting pancreatic cancer in transgenic mouse model J Feng, S Thomas, E Allen, A Iyer, D Hanahan, K Kelly, H VanBrocklin, ... Journal of Nuclear Medicine 51 (supplement 2), 251-251, 2010 | | 2010 |
